MedTrace Logo

A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT03607487 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-08-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.

Conditions

Interventions

DRUG

INCB054707

INCB054707 tablet administered orally once daily at the protocol-defined dose.

DRUG

Placebo

Placebo tablet administered orally once daily.

Sponsors & Collaborators

Principal Investigators

  • Kathleen Butler, MD · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2019-08-13
Completion
2019-08-13
FDA Drug
Yes

Countries

  • Canada
  • Denmark
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03607487 on ClinicalTrials.gov